Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.

[1]  H. Berendsen,et al.  ALGORITHMS FOR MACROMOLECULAR DYNAMICS AND CONSTRAINT DYNAMICS , 1977 .

[2]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[3]  J A McCammon,et al.  Theoretical calculation of relative binding affinity in host-guest systems. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Beveridge,et al.  Free energy via molecular simulation: applications to chemical and biomolecular systems. , 1989, Annual review of biophysics and biophysical chemistry.

[5]  J. Åqvist,et al.  Ion-water interaction potentials derived from free energy perturbation simulations , 1990 .

[6]  B. Mylari,et al.  Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. , 1991, Journal of medicinal chemistry.

[7]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[8]  F A Quiocho,et al.  Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[10]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[11]  K. Sharp,et al.  Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .

[12]  B. Honig,et al.  Classical electrostatics in biology and chemistry. , 1995, Science.

[13]  K. Bohren,et al.  Mechanism of human aldehyde reductase: characterization of the active site pocket. , 1995, Biochemistry.

[14]  H. G. Petersen.  Accuracy and efficiency of the particle mesh Ewald method , 1995 .

[15]  Gregory D. Hawkins,et al.  Parametrized Models of Aqueous Free Energies of Solvation Based on Pairwise Descreening of Solute Atomic Charges from a Dielectric Medium , 1996 .

[16]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[17]  D. Moras,et al.  A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. , 1997, Structure.

[18]  G. Rastelli,et al.  Structure-based design of an inhibitor modeled at the substrate active site of aldose reductase , 1997 .

[19]  M. Murata,et al.  Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners. , 1998, Journal of medicinal chemistry.

[20]  Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestat. , 1998, Bioorganic & medicinal chemistry letters.

[21]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.

[22]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[23]  G. Rastelli,et al.  Diabetes complications and their potential prevention: Aldose reductase inhibition and other approaches , 1999, Medicinal research reviews.

[24]  G. Rastelli,et al.  Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a potential substrate for new aldose reductase inhibitors. , 1999, Journal of medicinal chemistry.

[25]  D. Moras,et al.  Binding of aldose reductase inhibitors: correlation of crystallographic and mass spectrometric studies , 1999, Journal of the American Society for Mass Spectrometry.

[26]  Araz Jakalian,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method , 2000 .

[27]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[28]  The structure of human aldose reductase bound to the inhibitor IDD384. , 2000, Acta crystallographica. Section D, Biological crystallography.

[29]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[30]  Thomas Lengauer,et al.  FlexE: efficient molecular docking considering protein structure variations. , 2001, Journal of molecular biology.

[31]  Barry Honig,et al.  Extending the Applicability of the Nonlinear Poisson−Boltzmann Equation: Multiple Dielectric Constants and Multivalent Ions† , 2001 .

[32]  B. Matthews,et al.  A model binding site for testing scoring functions in molecular docking. , 2002, Journal of molecular biology.

[33]  The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat. , 2002, Acta crystallographica. Section D, Biological crystallography.

[34]  Wei Zhang,et al.  A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..

[35]  G. Klebe,et al.  Strategies for the design of inhibitors of aldose reductase, an enzyme showing pronounced induced-fit adaptations , 2004, Cellular and Molecular Life Sciences CMLS.

[36]  O. El-Kabbani,et al.  Structure of human aldose reductase holoenzyme in complex with Statil: An approach to structure‐based inhibitor design of the enzyme , 2002, Proteins.

[37]  A. Joachimiak,et al.  Subatomic and atomic crystallographic studies of aldose reductase: implications for inhibitor binding , 2004, Cellular and Molecular Life Sciences CMLS.

[38]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[39]  T. Tomizaki,et al.  Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors , 2004, Proteins.

[40]  Charles L. Brooks,et al.  Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures , 2004, J. Comput. Chem..

[41]  Michael Feig,et al.  Implicit solvation based on generalized Born theory in different dielectric environments. , 2004, The Journal of chemical physics.

[42]  J. Sredy,et al.  Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications. , 2004, Bioorganic & medicinal chemistry.

[43]  T. Tomizaki,et al.  High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor. , 2004, Journal of medicinal chemistry.

[44]  R. Lester.  Activation and desensitization of heteromeric neuronal nicotinic receptors: implications for non-synaptic transmission. , 2004, Bioorganic & medicinal chemistry letters.

[45]  R E Cachau,et al.  Ultrahigh resolution drug design I: Details of interactions in human aldose reductase–inhibitor complex at 0.66 Å , 2004, Proteins.

[46]  The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48. , 2004, Acta crystallographica. Section D, Biological crystallography.

[47]  P. Oates,et al.  A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners. , 2005, Journal of Medicinal Chemistry.

[48]  B. Kuhn,et al.  Validation and use of the MM-PBSA approach for drug discovery. , 2005, Journal of medicinal chemistry.

[49]  David A Pearlman,et al.  Evaluating the molecular mechanics poisson-boltzmann surface area free energy method using a congeneric series of ligands to p38 MAP kinase. , 2005, Journal of medicinal chemistry.

[50]  T. Petrova,et al.  Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. , 2005, Journal of medicinal chemistry.

[51]  M. Erion,et al.  Computer-aided drug design strategies used in the discovery of fructose 1, 6-bisphosphatase inhibitors. , 2005, Current pharmaceutical design.

[52]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[53]  Gerhard Klebe,et al.  High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. , 2006, Journal of molecular biology.

[54]  D. Harrison,et al.  Structural and thermodynamic studies of simple aldose reductase-inhibitor complexes. , 2006, Bioorganic chemistry.

[55]  Kun Song,et al.  Insight through molecular mechanics Poisson-Boltzmann surface area calculations into the binding affinity of triclosan and three analogues for FabI, the E. coli enoyl reductase. , 2006, Journal of medicinal chemistry.

[56]  Thomas Steinbrecher,et al.  A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase. , 2006, Journal of medicinal chemistry.

[57]  Paul A. Bates,et al.  Can MM‐PBSA calculations predict the specificities of protein kinase inhibitors? , 2006, J. Comput. Chem..

[58]  Ingebrigt Sylte,et al.  Molecular insight into pseudolysin inhibition using the MM-PBSA and LIE methods. , 2006, Journal of structural biology.

[59]  U. Ryde,et al.  Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. , 2006, Journal of Medicinal Chemistry.

[60]  Paul D Lyne,et al.  Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.

[61]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.